Beware of recruiting scams: Biora Therapeutics is not currently hiring.
Biora Therapeutics Home
Activate the mobile navigation

Publications

Single ascending dose results from a Phase 1 clinical trial of BT-600, a combination product of the NaviCap™ targeted oral delivery platform and tofacitinib
#Targeted Therapeutics
Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
#Targeted Therapeutics
Potential effects of food on a novel Drug Delivery System (DDS) to deliver therapeutic compound into the colon
#Targeted Therapeutics
Development of a novel Drug Delivery System (DDS) to deliver drugs directly to the colonic mucosa to improve efficacy and reduce systemic exposure for the treatment of ulcerative colitis (UC)
#Targeted Therapeutics
A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System (DDS) device in patients with active ulcerative colitis in fasted state
#Targeted Therapeutics
A scintigraphic study to evaluate the safety, tolerability, and functionality of a Drug Delivery System (DDS) device in healthy volunteers in fasted state
#Targeted Therapeutics
Pilot study to assess pharmacokinetic and pharmacodynamic markers following enema-dosing with adalimumab in patients with active ulcerative colitis
#Targeted Therapeutics
Pharmacokinetic stratification of cytokine profiles during anti-TNF induction treatment in moderate-to-severe ulcerative colitis
#Targeted Therapeutics
Tofacitinib tissue exposure correlates with endoscopic outcome
#Targeted Therapeutics